Hyperlipidemia is a chronic disorder which plays an important role in the development of cardiovascular diseases, type 2 diabetes, atherosclerosis, hypertension, and nonalcoholic fatty liver disease. Genipin (GNP) is a metabolite from genipioside, which is an active component of the traditional Chinese medicine Gardenia jasminoides Ellis, and has been recognized as a beneficial compound against metabolic disorders. However, whether it can correct overnutrition-induced dyslipidemia is still unknown. In this study, the effects of GNP on attenuating hyperlipidemia and hepatic lipid accumulation were investigated using normal and obese mice induced with a high-fat diet (HFD) and primary hepatocytes treated with free fatty acids. We also sought to identify potential targets of GNP to mediate its effects in the liver. We found that obese mice treated with GNP showed a decrease in the body weight, serum lipid levels, as well as hepatic lipid accumulation. Besides, GNP regulated hepatic expression levels of lipid metabolic genes, which are important in maintaining systemic lipid homeostasis. At the molecular level, GNP increased the expression levels of miR-142a-5p, which bound to 3 0 untranslated region of Srebp-1c, an important regulator of lipogenesis, which thus led to the inhibition of lipogenesis. Collectively, our data demonstrated that GNP effectively antagonized HFD-induced hyperlipidemia and hepatic lipid accumulation in mice. Such effects were achieved by regulating miR-142a-5p/SREBP-1c axis.
Introduction
Hyperlipidemia is a chronic disorder usually caused by excess nutrients which is characterized by high levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol, and a decreased level of highdensity lipoprotein cholesterol [1] . Long-term hyperlipidemia induces aberrant lipid accumulation in peripheral tissues, and therefore is associated with the development of cardiovascular diseases, type 2 diabetes, hypertension, and nonalcoholic fatty liver disease, leading to hepatic steatosis and liver damage [2] . It is estimated that the number of people with dyslipidemia will reach 78 million by 2022 [3] . Thus, hyperlipidemia has become a worldwide health crisis and imposes a substantial burden not only on personal health but also on societies and economies as a whole.
Lipids, acquired from the diet or synthesized endogenously in the liver and stored in the adipose tissue, are under a delicate balance regulation between lipid accumulation and energy utilization. Dietary fat incorporated into chylomicron are transported by apolipoproteins, which can interact with cellular receptors to determine the fate of phospholipid metabolism. The chylomicron remnants are either taken up by the hepatic low-density lipoprotein receptor (LDLR) or released free fatty acids (FFAs) and then absorbed into hepatocytes through CD36 [4] . Also, the body is able to mobilize and excrete cholesterol and other lipids through ATP-binding cassette transporter superfamily, including ABCA1, ABCG5, and ABCG8, as opposed to the LDLR [5] . The first rate-limiting step in fatty acid synthesis is the conversion of acetyl-CoA to malonyl-CoA by the enzyme acetyl-CoA carboxylase. Palmitic acid is carried out by fatty acid synthase (FAS) and elongated by fatty acyl-CoA elongase family members to generate long-chain fatty acids (LCFAs). The unsaturated fatty acid is the final product of the stearoyl-CoA desaturases (SCD1) mediating fatty acid biosynthesis [6] . Of note, SREBP-1c, a member of sterol regulatory element-binding proteins (SREBPs), is an indicator of disrupted lipid homeostasis which is abundantly expressed in the liver and activates the genes that control fatty acid synthesis [7, 8] . In contrast to lipid synthesis, liver fatty acid oxidation (FAO) is taken place in mitochondrial and provides energy for hepatocytes. The rate-limiting step is LCFA-CoA translocation into the mitochondria, which is mediated by carnitine palmitoyl-transferase 1a (CPT1a). PPARa, a nuclear receptor family member of the peroxisome proliferator activated receptors (PPARs), is a lipid sensor that controls energy homeostasis and is activated by a subtype of LCFAs to promote FAO in both mitochondria and peroxisomes [9, 10] . Thus, regulation of lipid generation and expenditure is crucial in determining circulating lipid levels.
Moreover, recent studies indicated that microRNAs (miRNAs) emerge as novel biomarkers and potential therapeutic targets in the treatment of hyperlipidemia and hepatic lipid dysregulation [11] . MiRNAs, which are small noncoding RNAs molecules composed of 19-25 nucleotides, have been implicated in the regulation of a wide spectrum of biological processes through binding to the 3 0 UTR of target genes and further inducing mRNA destabilization and/or translational repression [12] . For example, miR-122, a wellknown miRNA, has been demonstrated to regulate fatty acid metabolism through targeting SREBP-1c [13] . And miR-34a could regulate hepatic steatosis by targeting PPARa [14] . Additionally, miRNAs also play important roles in other aspects of hyperlipidemia, such as obesity, type 2 diabetes, and atherosclerosis stresses [15] . Thus, selecting functional miRNAs is a convincing strategy to treat hyperlipidemia and hepatic lipid dysregulation.
The treatments of hyperlipidemia include lifestyle adjustments (integration of diet and exercise) if necessary in combination with drug therapy, such as stain, niacin, fibrates, omega-3-fatty acids, and so on [16] . Surgery is also a powerful method [17] . However, most of these approaches have adverse effect (e.g., myalgia, fatigue, dyspnea, memory loss, and peripheral neuropathy) in patients [18] . Thus, many research efforts have focused on development of the traditional Chinese medicine, an excellent representative in alternative and complementary medicines with a complete theory system and substantial herb remedies [19] . Of particular interest, Gardenia jasminoides Ellis is an evergreen shrub that is mostly distributed in the southern regions of China [20] . The extract of G. jasminoides Ellis fruits possesses cholagogue [21] , anti-inflammatory [22] , antitumor [23] , and antioxidative effects [24] . Genipin (GNP), an iridoid glucoside aglycone and a major component of Gardenia fruits, has been showed to have versatile biological and pharmacological activities [25, 26] . Specially, GNP potentially regulates lipid metabolism. For example, administration of GNP antagonizes aging-related hepatic steatosis in rats [27] . In another study, GNP has been showed to suppress the intracellular lipid accumulation caused by the treatment of FFAs in liver HepG 2 cells [28] . However, the effects of GNP on malnutrition-induced metabolic disorder in vivo still need to be elucidated. Also, the direct molecular target of GNP in liver, the largest metabolic organ, remains unknown.
In the present study, high-fat diet (HFD)-fed hyperlipidemic mice were treated with GNP to explore its beneficial functions and the possible underlying molecular mechanism. Our results indicated that GNP reversed metabolic abnormalities in these mice by regulating miR-142a-5p/SREBP-1c axis, therefore potentially serving as an additional therapeutic intervention in the arsenal against hyperlipidemia.
Results
Genipin reduces body weight gain and increases locomotor activity in HFD-fed obese mice When fed HFD for 2 months, mice had a significant increase in the body weight (BW) than normal diet (ND) groups. In the following time period of GNP treatments (for another 9 weeks), the obesity of these mice receiving saline gavage (as control) became more severe (6.34 g of the BW gain at the end of experiment). In contrast, the average BW gain of HFD-fed obese mice treated with GNP at 5 mgÁkg
À1

Áday
À1 was only 4.22 g, and the high dose ) by gavage. (A) Body weight and (B) Food intake were examined. Data of food intake were analyzed by an ANCOVA analysis using BW as a covariant. (C) Fasting insulin levels were examined in the mouse serum. After 9 weeks of genipin treatments, (D) RQ; (E) VO 2 ; (F) EE; (G) locomotor activity were assayed and (H) GTTs; (I) ITTs; (J) PTTs were performed. The relative areas under the curves (AUC) were also calculated and shown. Data were presented as mean AE SD, n = 6 mice per group. **P < 0.01 vs. ND, HFD-induced obesity in mice. However, GNP did not show any apparent effect on food intake either in the two ND-fed groups or in the three HFD-fed groups, suggesting that GNP did not affect appetite (Fig. 1B) . We next monitored fasting insulin levels in these animals since GNP has been reported to increase insulin secretion in pancreatic b-cells [29] . As expected, HFD feeding led to hyperinsulinemia and the fasting insulin levels in HFD-fed mice were remarkably increased (5.5-fold compared to ND-fed lean mice). To our surprise, GNP treatments did not show a significant regulation in plasma insulin levels (Fig. 1C) .
The energy homeostasis is achieved by balancing caloric intake and energy expenditure (EE). As the food intake was not altered by GNP, we next investigated EE in mice subjected to metabolic cages. We found that while the respiratory quotient (RQ) was not changed (Fig. 1D) , EE and the oxygen consumption (VO 2 ) were significantly increased in response to the treatment of high dose of GNP (Fig. 1E,F) . Consistently, the spontaneous locomotor activity was also increased (Fig. 1G) . Hence, GNP effectively attenuated BW gain and increased locomotor activity in mice fed with a HFD.
Genipin improves insulin resistance in HFD-fed obese mice
Since GNP reduced BW gain and increased activity, we next test whether it could protect against obesity-induced insulin resistance and glucose dysregulation by using GTT, ITT, and PTT assays. As shown in Fig. 1H -J, HFD feeding impaired both glucose and pyruvate tolerance and caused insulin resistance. In contrast, supplementation with GNP significantly attenuated the decrease in glucose tolerance, while leaving pyruvate tolerance unchanged. These results demonstrated that administration of GNP is capable of maintaining glucose homeostasis in the overnutritional setting, and may have a minor effect on the hepatic gluconeogenesis.
Genipin alleviates hyperlipidemia and decreases lipid accumulation in the liver of HFD-fed obese mice
To determine the possible hypolipidemic effect of GNP on HFD-fed obese mice, the serum lipid profile was examined. As expected, 2-month HFD feeding led to a robust increase in serum TG and TC levels ( Fig. 2A ,B, 1.6-and 2.2-fold, respectively, compared to the ND feeding group). Notably, GNP administration efficiently inhibited such increases in a dose-dependent manner. On the other hand, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are two biomarkers of liver injury. We found that GNP antagonized HFD feeding-induced increase in the serum levels of ALT and AST (Fig. 2C,  D) , suggesting that GNP possesses a hepato-protective effect.
Consistent with the increases of serum lipids, morphological observations indicated that HFD-fed mice had striking epididymal fat accumulation (Fig. 2E) . The liver of these mice was larger and the color turned yellow, suggesting the occurrence of lipid accumulation and liver steatosis (Fig. 2E) . Indeed, HFD significantly increased the ratio of liver weight to BW, and the hepatic levels of TG and TC ( Fig. 2F-H ). All these abnormalities in epididymal fat and in liver were alleviated by GNP. In addition, GNP increased ATP production in liver in a dose-dependent manner (Fig. 2I ). H&E and oil red O staining in liver sections also confirmed that GNP inhibited HFD-induced severe hepatic fat accumulation (Fig. 2J ).
Genipin regulates lipid metabolic gene expression in HFD-fed obese mice
Lipid homoeostasis is mainly regulated by four processes, including apolipoprotein synthesis, lipid transport, lipogenesis, and FAO. To determine the effects of GNP on lipid metabolism at the molecular levels, the hepatic expression levels of major regulators involved in these four processes were determined.
As the hydrophobic molecules, cholesterol, and TGs are transported via apolipoproteins to tissues for energy utilization, lipid storage, or hormone synthesis, we found that HFD feeding increased the mRNA expression levels of all examined apolipoproteins, including Apoa4, Apob48, Apoc1, Apoc2, and Apoe. GNP roughly did not alter their expression, and only increased Apoa4 expression in liver tissues (Fig. 3A) . The expression of Ldlr, Abca1, Abcg5, and Abcg8, which are responsible for hepatic lipid load and absorption of dietary fat, also remained unchanged in general in response to HFD feeding and GNP administration, except for Cd36 (Fig. 3B) . Interestingly, HFD-fed mice had a robust increase in hepatic expression levels of lipogenic genes, including Srebp1c, Acc1, Fas, and Scd1. Conversely, GNP inhibited their expression in a dose-dependent manner (Fig. 3C) . Lastly, no significant change in FAO gene expression was observed in our settings (Fig. 3D ). Based on these findings, we concluded that GNP may regulate lipid homeostasis through inhibiting lipogenesis pathway.
To confirm the regulatory role of GNP in lipogenic gene expression, we examined the protein expression levels in liver samples and found a similar trend compared to mRNA expression (Fig. 3E,F) . GNP inhibited HFD feeding-induced upregulation of the hepatic protein expression levels of SREBP-1c, FAS, and SCD1 in a dose-dependent manner.
Genipin reduces lipid accumulation and inhibits lipogenic gene expression in mouse primary hepatocytes
We next performed cell culture experiments to assess the function of GNP in the regulation of lipid metabolism in vitro. Firstly, the cytotoxicity of GNP in mouse primary hepatocytes was evaluated to determine nontoxic condition of gnipin for the cells. The CCK-8 assay results revealed that GNP at a concentration of 20 lM or lower did not inhibit cell viability over 36 h or less (Fig. 4A,B) . We therefore selected 5 and 20 lM of GNP for 24 h as the safe status for hepatocytes and used them throughout our study.
Oil red O staining showed that lipid accumulation was robustly increased in hepatocytes when treated with FFAs (Fig. 4C) . Treatment of GNP alleviated lipid accumulation in a dose-dependent manner. Coinciding with these observations, GNP also decreased TG levels both in the cells and in the culture medium (Fig. 4D,E) . At the molecular levels, GNP inhibited protein expression levels of SREBP1c, FAS, and SCD1 in FFA-treated mouse primary hepatocytes (Fig. 4F,G) . Taken together, GNP could efficiently block lipogenic process both in vivo and in vitro.
MiR-142a-5p inhibits Srebp-1c 3
0 UTR activity SREBP-1c is a dominant transcription factor orchestrating lipogenesis. The regulation of SREBP-1c has been intensively studied and recently, it has been shown that in addition to those traditional factors, miRNAs also play important roles in maintaining normal SREBP-1c-mediated lipogenesis. As GNP antagonized HFD feeding-induced SREBP-1c expression both at mRNA and protein levels, we sought to figure out potential miRNAs mediating the inhibitory effects of GNP on SREBP-1c expression. Bioinformatics analysis using TargetScan, miRNA, miRDB, and DIANAmT tools have identified six miRNAs potentially binding and targeting to the 3 0 UTR region of Srebp1c, including miR-142a-5p, miR-132-3p, miR-212-3p, miR-33-5p, miR-340-5p, and miR-18b-5p (Table 1) . Among which, the hepatic expression levels of miR-212-3p, miR-340-5p, and miR-18b-5p were very low [30] . Besides, miR-122-5p, miR-185-5p, and miR-370-3p were reported to target SREBP-1c and regulate the hepatic lipogenesis [31] [32] [33] . Therefore, these miRNAs were selected for RT-qPCR validation. The results demonstrated that only miR-142a-5p could be increased by GNP (Fig. 5A ). To investigate in vivo regulation of miR-142a-5p by GNP under pathophysiological conditions, we again used RT-qPCR analysis to quantify the hepatic expression levels of miR-142a-5p of obese and lean mice before and after GNP treatments. Our results indicated that HFD feeding alone increased its expression level to 1.4-fold, and GNP treatments further up-regulated it expression to 2.3-fold, compared to the ND group (Fig. 5B) . However, GNP did not alter the expression levels of this miRNA in the liver of lean mice. These results indicated miR142a-5p may be the node linking GNP's hypolipidemic effect and SREBP-1c-mediated lipogenic pathway.
To test our hypothesis, we constructed a luciferase reporter vector containing mouse Srebp-1c 3 0 UTR region and transfected it into AML12 liver cells. This region had a predicted binding site for miR-142a-5p, which was 838 nucleotides long (Fig. 5C ). Simultaneously, a parallel vector containing a mutated miR142a-5p putative binding site on Srebp-1c 3 0 UTR region was also constructed (Fig. 5D) . Luciferase reporter assays indicated that transfection of miR142a-5p mimic reduced the activity of Srebp-1c 3 0 UTR region by 75% (Fig. 5E ), while transfection of miR142a-5p inhibitor had an opposite effect (Fig. 5F ). However, a mutation in miR-142a-5p putative binding site on Srebp-1c 3 0 UTR region almost completely abolished the effects of miR-142a-5p mimic and inhibitor (Fig. 5E,F) , indicating that this binding site is essential for the function of miR-142a-5p. Functionally, protein expression analysis showed that miR-142a-5p mimic (transfection efficiency was shown in Fig. 5G ) reduced SREBP-1c expression (Fig. 5H) . As a conclusion, miR142a-5p is a negative regulator of SREBP-1c.
MiR-142a-5p mediates inhibitory effects of genipin on SREBP-1c and lipid accumulation
To explore the role of miR-142a-5p in mediating the effects of GNP, primary hepatocytes were transfected with miR-142a-5p inhibitor and treated with GNP, relative miR-142a-5p expression was assayed to show the knockdown efficiency (Fig. 6A) . We found that inhibition of miR-142a-5p significantly blocked the repressive effect of GNP on lipogenic proteins SREBP-1c and FAS (Fig. 6B,C) . Functionally, GNP failed to inhibit intracellular lipid accumulation in FFA-treated hepatocytes with miR-142a-5p knockdown (Fig. 6D) . Consistently, TG levels both in the cells and culture medium were partially recovered when miR-142a-5p was knocked down in the presence of GNP (Fig. 6E,  F) . Collectively, our findings strongly suggested that miR-142a-5p mediates inhibitory effects of GNP on SREBP-1c and lipid accumulation.
Discussion
In this study, we explored the effects of GNP on attenuating hyperlipidemia and hepatic lipid accumulation by using normal and obese mice induced by a HFD and primary hepatocytes treated with FFAs. Our findings indicated that GNP reduced BW gain and increased locomotor activity, alleviated hyperlipidemia, and decreased hepatic lipid accumulation. At the molecular level, GNP decreased lipogenesis via regulation of miR-142a-5p/SREBP-1c axis. Thus, GNP has potentials for clinic use as a lipid-lowering agent to treat hyperlipidemia and related metabolic disorders.
Drugs from natural products have distinct advantages, such as extensive resources, fewer advance effects, and definitive action in lowering lipids [19] . The extract of G. jasminoides Ellis fruits has been used over the years to treat metabolic symptoms [34] . Specifically, GNP was identified as an inhibitor of mitochondrial uncoupling protein 2 (UCP2) [29] , a gene which is widely expressed in mammalian tissues and mediates energy dissipation. Although many pharmacological effects of GNP are dependent on UCP2 inhibition, such as reverse of pancreatic b-cell dysfunction induced by obesity and hyperglycemia [29, 35] , another mechanism seems to be involved in the protective roles of GNP in treating metabolic syndrome, because UCP2 deficiency does not affect the severity of obesity-related fatty liver [36] . This hypothesis prompted us to explore new molecular mechanism for GNP's beneficial effects.
The regulation of pancreatic islets function by GNP may be complex. Zhang et al. [29] firstly reported that GNP increased insulin secretion in cultured pancreatic b cells. On the other hand, plasma insulin levels were decreased in spontaneously obese type 2 diabetic TSOD mice when geniposide (the inactive precursor of GNP, which is transformed into GNP by intestine microbiota) was given in the mixture of powder food [28] . In our study, GNP treatments did not show a significant regulation in plasma insulin levels (Fig. 1C) . Based on previous reports and our data, we speculate that the regulation of insulin secretion by GNP may be dependent on the dose, treatment time, and the administration approaches. On the other hand, we noticed that the response to insulin over the first 30 min of the ITT assays was identical in each of the HFD-fed groups. Only the final 60-120-min phase of the test was different. This observation suggested that GNP may not directly regulate insulin sensitivity. Instead, counter-regulatory responses may be responsible for causing the difference of ITT assays. Coincided with our hypothesis, a recent report demonstrated a negative regulation of glucagon secretion from pancreatic a-cells by GNP, leading to hypoglycemia [37] . Therefore, the crosstalk between glucagon and insulin secretion regulated by GNP in pancreatic islets comprehensively determines the final outcomes of systemic glucose homeostasis.
Although several studies have already focused on the regulation of lipid metabolism by GNP, their findings are somehow controversial. By using FFA-treated HepG 2 cells, Kojima and colleagues found that GNP suppressed the intracellular lipid accumulation and significantly increased the expression levels of PPARa, a FAO-related gene [28] . Coinciding with this finding, an in vivo study indicated that GNP ameliorated aginginduced insulin resistance, hyperinsulinemia, hyperglyceridemia, and hepatic steatosis, and relieved hepatic oxidative stress and mitochondrial dysfunction in rats [25] . In contrast, Ma et al. [38] suggested that GNP exacerbated palmitic acid-induced lipid accumulation and superoxide production in HepG 2 cells. Therefore, the exact function of GNP in lipid homeostasis should be re-evaluated. In our present study, we found that chronic treatment of GNP (9 weeks) significantly inhibited HFD feeding-induced hyperlipidemia and liver lipid contents in mice. To the best of our knowledge, this is the first time to confirm positive role of GNP in the protection against hyperlipidemia in the overnutrition mouse model. As expected, we cannot exclude the possibility that the dose and treatment time of GNP, as well as the in vitro models used (primary mouse hepatocytes vs. liver carcinoma cells HepG 2 ), may affect the overall effects of GNP observed.
Since GNP inhibits lipid accumulation both in vivo and in vitro, we sought to determine the related molecular mechanism. As is known, lipid metabolism mainly includes four pathways, including lipoprotein synthesis, lipid transport, de novo lipogenesis, and FAO [6] . RT-qPCR analysis in classic mark genes involved in these four pathways helped us to narrow down major targets of GNP and we found that only regulators in lipogenesis, specifically Srebp-1c, were robustly inhibited by GNP. Of note, SREBP-1 c is the most important transcription factor in hepatic lipogenesis and plays a considerable role in the pathogenesis of hyperlipidemia [7] . To date, many natural products show a regulatory effect on SREBP-1c-mediated lipogenesis, such as silymarin [39] , curcumin [40] , oleanolic acid [41, 42] , mangiferin [43] , and so on. Our findings provided new compounds targeting SREBP-1c and will shed some light on the chemical modification of GNP to generate more specific inhibitor for SREBP-1c. Future studies are required to further elucidate the regulation of SREBP-1c by GNP, including the nuclear localization and post-translational modification of SREBP-1c.
Several lines of evidence have demonstrated that GNP effectively regulates multiple physiological processes in metabolic tissues/cells, leading to a comprehensive modulation. For example, in C 2 C 12 myotubes, GNP increases insulin sensitivity by regulating GLUT4 translocation and promoting glucose uptake [26] . More importantly, pharmacological administration of GNP restores glucose sensing in POMC neurons of HFDfed obese mice [44] . In contrast, GNP reduces insulinstimulated glucose uptake through the inhibition of UCP2 in 3T3-L1 adipocytes [45] . As a conclusion, the effects of GNP on energy metabolism in various metabolic tissues may counteract, and the functional threshold of GNP may differ when targeting different physiological activities, causing weaker phenotypes observed in mice treated with low dose of GNP (no effect on EE, VO 2 , locomotor activity, and liver miR142a-5p expression, while still altering metabolic parameters such as BW, GTT, and ITT measures). On the other hand, GNP possibly affects energy metabolism through interaction with gut microbiota. As is known, the gut microbiota plays an important role in the regulation of nutrient acquisition and BW, thus serving as a key factor to sense and integrate multiple factors leading to obesity. More interestingly, the composition of gut microbiota oscillates according to the 24-h dark/light cycles [46] , implicating its correlation with the circadian clock system. A recent report demonstrated that the rhythmic metabolome atlas of the intestinal microbiota regulates the temporal organization and functional outcome of host physiological processes [47] . Notably, GNP only affected mouse activity of HFD-fed mice in the dark phase (data not shown), suggesting that gut microbiota potentially serve as another target of GNP and GNP may specifically regulate those flora enriched in the intestine of HFD-fed mice, leading to the specific changes in the diurnal activity of these mice. In fact, although we still do not know how GNP affects intestinal microbiota, two recent studies already revealed the interaction between intestinal microflora and geniposide, the precursor of GNP [48, 49] . If our hypothesis is true, GNP' effects are likely dependent on the type of feeding and are more powerful to antagonize deleterious outcomes of the Western diet.
As endogenous small noncoding RNAs, miRNAs regulate gene expression through binding to their complementary sites within the 3 0 UTR region of target mRNAs, which leads to the translational repression or transcript degradation of these mRNAs [50] . It is estimated that approximately 30% of the protein-coding genes are regulated by miRNAs, therefore affecting almost all the cellular physiological processes [51] . Without exception, certain miRNAs play significant roles in the regulation of hepatic lipid metabolism including de novo lipogenesis (miR-122, miR-370, miR-33a/b), fatty acid uptake (miR-467b, miR-29a, miR-21), FAO (miR-199a, miR-33, miR-10b), and export of TG (miR-122 and miR-30c) [52] . As a critical regulator involved in hepatic lipogenesis, SREBP1c also interacts with miRNAs [53] . For example, miR-33 reduces SREBP-1c protein expression and deletion of miR-33 results in marked worsening of HFD-induced obesity and liver steatosis in mice [54] . We also found that in response to GNP treatments, miR-142a-5p inhibited SREBP-1c mRNA expression in the liver. Currently, the physiological roles of miR142a-5p have not been well studied. Only a few reports indicated that miR-142a-5p is involved in vascular development and integrity [55] , neutrophil development [56] , and inflammation and T-cell differentiation [57] . Our results extended the recognition of miR142a-5p functions and given the importance of SREBP-1c in the control of lipid homeostasis, suppression of SREBP-1c by miR-142a-5p would establish a connection among diverse pathophysiological conditions such as hyperlipidemia, cardiovascular remodeling, and innate immunity. Of note, HFD feeding alone already increased hepatic miR-142a-5p expression in our system, and GNP treatments further up-regulated its expression levels, suggest that the induction of miR-142a-5p by HFD feeding may be insufficient to antagonize lipid accumulation. Only when this miRNA is dramatically increased to a certain threshold, can it be able to manifest a hypolipidemic effect through regulating SREBP-1c.
In conclusion, we found that GNP effectively antagonized HFD-induced hyperlipidemia and hepatic lipid accumulation in mice. Such effects were achieved by regulating miR-142a-5p/SREBP-1c axis (Fig. 6G) . Because GNP has been reported to possess other beneficial functions in the energy metabolism, such as improving pancreatic b-cell function, this compound may serve as a versatile drug to treat metabolic disorders by hitting multiple organs in a "killing two birds with one stone" manner.
Materials and methods
Animals
The animal procedures in this study conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication 85-23, revised in 1996) and the approved regulations set by the Laboratory Animal Care Committee at Nanjing Normal University (Permit 2090658, issued 20 April 2008). Fifty male C57BL/6J (6-8 weeks old) mice were purchased from the Model Animal Research Center of Nanjing University (Nanjing, Jiangsu, China). The mice were housed in the animal facilities which had free access to water and food with a 12 : 12-h light/dark cycle, controlled temperature (22-24°C), and humidity (50-60%). After 1-week quarantine period, mice were randomly divided into two groups, 20 were given ND (Research Diets, Xietong Organism, Nanjing, Jiangsu, China) and 30 were fed HFD (Research Diets). Two months later, these mice were assigned into five groups (with 10 mice per group): ND with saline (ND + Saline), ND with 20 mgÁkg (C11H14O5, HPLC ≥ 98%; Zelang, Nanjing, Jiangsu, China) was dissolved in the saline solution and was given to mice everyday by oral gavage for 9 weeks. The doses of GNP were selected based on a previous report showing that 50 mgÁkg À1 Áday À1 GNP ameliorated podocyte injury in streptozocin-induced diabetic nephropathy mice [58] . Equal volumes of saline solution were infused to mice as control. BW and food intake were monitored every week.
Metabolic chamber
Two weeks before sacrifice, the metabolic rates of mice were assayed with a comprehensive laboratory animal monitoring system (Panlab, Harvard apparatus, Holliston, MA, USA). Mice were caged individually and acclimated for 1 week before testing. Measurements were conducted over a 12 : 12-h light/dark cycle for 3 days during which the animals had ad libitum access to food and water. Data on EE, oxygen consumption (VO 2 ), spontaneous physical movement, and food intake were measured simultaneously for each mouse. RQ equals volumes of CO 2 released/ volumes of O 2 consumed.
Glucose, pyruvate, and insulin tolerance tests 
Immunohistochemically staining
Mouse liver tissues were harvested, frozen immediately in liquid nitrogen, and stored at À80°C for subsequent analysis. A small piece of liver was cut and submerged in 4% paraformaldehyde for hematoxylin and eosin staining (H&E) and oil red O staining (Service Biology, Wuhan, Hubei, China).
Biochemical analysis
Blood samples were collected from the retro-orbital plexus of mice and transferred into centrifuge tubes. After stewed overnight at 4°C, bloods were centrifuged at 3000 g for 10 min. Serum were then collected from supernatant and stored at À80°C for subsequent analysis. Serum insulin levels were measured using the mouse insulin ELISA kit (Millipore, Billerica, MA, USA 
Luciferase reporter construction
The 3 0 UTR region (838 nucleotides) of mouse Srebp-1c gene containing a putative target site for miR-142a-5p was from NCBI (https://www.ncbi.nlm.nih.gov/nuccore/NM_0013139 79.1) and amplified by PCR using primers listed in Table S1 , and was inserted between XhoI and BamHI restriction enzyme cutting sites, immediately downstream of the luciferase gene in the CMV-Luciferase-MCS Vector. We also mutated 7 bp of the miR-142a-5p-binding site from ACTT-TAT to CACGCGC. Wild-type (WT) and mutant (Mut) inserts were confirmed by sequencing and transfected into AML12 liver cells. After transfection, cells were lysed and supernatants were collected for analysis after centrifuged at 13 500 g for 2 min at 4°C. Relative luciferase activities (ratio of Renilla luciferase signal normalized to Firefly luciferase) were measured with commercially available test kits (E1910; Promega, Madison, WI, USA) and examined by Luminoscan Ascent (Thermo Fisher Scientific).
Quantitative real-time RT-PCR
Total RNA in liver tissues and primary hepatocytes were extracted using TRIzol reagents (Invitrogen, Carlsbad, CA, USA). cDNA were obtained from total RNA by a reverse transcription kit (Takara, Dalian, China). Gene expressions were measured using qPCR (Lightcycler 96; Roche) via SYBR green kits (Vazyme, Nanjing, Jiangsu, China). A complete list of the primers was showed in Table S1 . 36B4 and U6 snRNA were used to normalize mRNA and miRNA levels, respectively.
Western blotting
For protein analysis, the harvested cells or the liver tissue homogenates were suspended in RIPA buffer containing a protease inhibitor cocktail (Roche) and PMSF (Beyotime).
Equal amounts of protein were loaded and separated by 10% SDS/PAGE and then transferred onto a polyvinylidene difluoride membrane (Millipore). The samples were blotted overnight using appropriate antibodies against SREBP-1c (Proteintech, Wuhan, Hubei, China), FAS (Proteintech), SCD1 (Santa Cruz, CA, USA), or b-Actin (Proteintech). These experiments were performed in triplicate. Quantitation of protein was performed using an AlphaEascFC system (FluorChem 8800).
Bioinformatics analysis
The potential miRNAs binding to Srebp-1c 3 0 UTR was predicted and integrated using the web-based bioinformatic prediction algorithms (TargetScan (http://www.targetscan.org/ mmu_71/) [59] , miRNA (http://www.microrna.org/microrna/ home.do) [60] , miRDB (http://mirdb.org/cgi-bin/search.cgi) [61, 62] , DIANAmT (http://diana.imis.athena-innovation.gr/ DianaTools/index.php?r=tarbase/index/) [63, 64] ). These algorithms have been widely used for miRNA targets prediction.
Statistical analysis
Data were presented as mean AE standard deviation (SD) from multiple samples. All experiments were repeated at least three times. Group differences were considered statistically significance at P < 0.05 assessed by Student's t-test or one-way ANOVA followed by Fisher's LSD post hoc test using Origin 8 (version 8.6; OriginLab Corporation, Northampton, MA, USA).
